Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas

Tipifarnib is a potent and highly selective inhibitor of farnesyltransferase (FT). FT catalyzes the post-translational attachment of farnesyl groups to signaling proteins that are required for localization to cell membranes. Although all RAS isoforms are FT substrates, only HRAS is exclusively depen...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Cancer Ther
Hlavní autoři: Gilardi, Mara, Wang, Zhiyong, Proietto, Marco, Chillà, Anastasia, Calleja-Valera, Juan Luis, Goto, Yusuke, Vanoni, Marco, Janes, Matthew R., Mikulski, Zbigniew, Gualberto, Antonio, Molinolo, Alfredo A., Ferrara, Napoleone, Gutkind, J. Silvio, Burrows, Francis
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7484242/
https://ncbi.nlm.nih.gov/pubmed/32727882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-19-0958
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky